IngredientsFucoidan (also historically spelled fucoidin) is a class of sulfated polysaccharides occurring naturally in brown seaweeds and in certain marine invertebrates. Fucoidan refers to a type of polysaccharide which contains substantial percentages of L-fucose and sulfate ester groups, mainly derived from brown seaweed. Fucans, including fucoidan, are sulfated polysaccharides — molecules made up of a number of sugar groups that also have sulfur atoms attached; the main sugar group is fucose, which has 6 carbon atoms and the chemical formula C6H12O5. The term "fucoidan" (or fucoidin) specifically indicates fucans derived from brown algae (seaweed).
Fucoidan is a sulphated polysaccharide made up mainly of L-fucose found in brown seaweeds; its chemical structure is diverse and depends on maturity, species, and geographical location. Three major structural types have been defined: F-fucoidan is almost completely composed of sulfated fucose (officially called sulfated fucan); G-fucoidan consists of sulfated fucose and sulfated galactose as its main components (also called sulfated galactofucan); and the third type, GA-fucoidan or U-fucoidan (uronofucoidan), is composed mainly of fucose accompanied by other monosaccharides — mostly mannose or galactose but also glucose, xylose, and rhamnose — with significant amounts of uronic acids and sulfate ester.
At the backbone level, two main molecular architectures have been described: Type 1 fucoidan molecules have a backbone of (1→3)-linked α-L-fucopyranose residues, where the "R" positions can carry monosaccharide or sulfate substituents; type 2 fucoidan has an alternating backbone, and the fucoidan from Fucus vesiculosus carries a backbone of alternating (1→3)-linked α-L-fucopyranose residues with sulfate groups on both O-2 and O-3 positions. Minor monosaccharides present in fucoidan from various species can include uronic acid, rhamnose, glucose, galactose, xylose, mannose, arabinose, ribose, and glucuronic acid.
These polysaccharides are characterized by possessing sulfate ester groups that impart negatively charged surfaces, and they may be of low or high molecular weight and are water soluble. The general bioactivity of fucoidan is difficult to establish due to factors such as species-related structural diversity, growth conditions, and the extraction method.
Fucoidan is a naturally derived compound found in different species of brown algae and in some animals. Commercially available fucoidan is commonly extracted from the seaweed species Fucus vesiculosus (wracks), Cladosiphon okamuranus, Laminaria japonica (kombu, sugar kelp), and Undaria pinnatifida (wakame). Additional brown seaweed species that have been explored as fucoidan sources include Ecklonia cava, Sargassum spp., Fucus evanescens, and numerous others.
Beyond algae, fucoidan is also found in the animal kingdom: echinoderms — including starfish, sea urchins, and sea cucumbers — also produce fucoidan; sea cucumber species that have been explored for fucoidan production include Apostichopus japonicus, Holothuria tubulosa, and Stichopus japonicus.
The physiological role of fucoidans in algae appears to be a role in cell wall organization and possibly in cross-linking of alginate and cellulose and morphogenesis of algal embryos.
Fucoidan is sold as a dietary supplement, food additive, and as an ingredient in animal feed or cosmetics. As a result of research, fucoidan extracts are now used in a variety of applications including dietary supplements, medical devices, veterinary products, and topical formulations for skincare and dermatology. Fucoidan extraction methods, purity, global regulatory approvals, and source seaweed species vary among fucoidan products.
Oral dosage forms — including capsules and powders — are the most common supplement presentations. Low-molecular-weight (LMW) fucoidan preparations have been developed to improve bioavailability: LMW showed higher absorption and better oral bioavailability compared to medium-molecular-weight (MMW) fucoidan. Oral delivery of fucoidan is limited by its low solubility in gastric fluid and poor intestinal absorption; this poor absorption has been attributed to the negatively charged sulfate ester groups, and capping these negative charges or adding an intestinal tight junction opening agent (such as berberine) are among the strategies adopted to enhance oral bioavailability.
In China, a standardized prescription product derived from fucoidan has received regulatory status: the effective constituent of Haikun Shenxi capsule (HSC) is the fucoidan extracted from Saccharina japonica, and HSC was approved for treating renal diseases by the Chinese Food and Drug Administration in 2003.
The earliest records of medicinal use of fucoidan-containing seaweeds occur at Monte Verde in southern Chile, where archaeological digs beginning in the 1970s began to unearth cuds of masticated seaweeds — some had been cooked and some mixed with other plants and chewed raw. Roman historian Pliny the Elder and Greek physician Dioscorides Pedanius recommended the consumption of seaweeds for therapeutic purposes, both reporting it was an excellent treatment for gout, rashes, intestinal problems, and liver disorders.
The Shen Nong Ben Cao Jing, which provides a summary of early Chinese medicinal knowledge before 25–220 AD, is the first known record of seaweed being used to treat disease. Fucoidan-containing seaweeds have been eaten and used medicinally for at least 3,000 years in Tonga and at least 2,000 years in China.
Fucoidan-containing seaweeds have been prized for their dietary and therapeutic properties for centuries; their medicinal properties have been particularly well documented in Asian cultures, where brown seaweeds have been used to address health conditions that range from nausea, congestion, and inflammation through to abscesses and tumours. Saccharina japonica is consumed as a marine vegetable in East Asia; over the past thousand years, Chinese people have traditionally used this plant to cure edema, a symptom of kidney diseases.
In Okinawa, Japan, fucoidan-containing seaweeds formed a central part of local cuisine and culture. In Okinawa — famous for its high number of centenarians — mozuku seaweed, which is rich in fucoidan, is a dietary mainstay. The remote geography of the island made livestock raising and farming difficult, so most food came from the waters around the island; Okinawans developed an entire cuisine based on local fucoidan-rich seaweeds, consuming them raw, using them as garnish with sake, and boiling them for soup stock.
Despite this long history of seaweeds as medicinal agents, it was not until the twentieth century that fucoidan was first isolated and recognised for its therapeutic potential. In 1913, Swedish chemist Professor Harald Kylin described the slimy film found on many seaweeds as fucoidan; he went on to characterise it in 1915, noting in detail its high fucose content, and other chemists followed his lead, analysing fucoidan molecules to determine that they are sulphated, fucose-rich polymers. In the late 1950s, its anticoagulant activity was established, and shortly thereafter its ability to bind to carbohydrates.
The biological activities of fucoidans depend on their composition — monosaccharides, sulfation degree, and position — as well as their structure, including glycosidic linkages, molecular weight, branching, and substitution degree, and the route of administration; additionally, the seaweed source, species, environmental and collecting area, and processing conditions strongly affect fucoidan composition and structure. Structure-activity relationship studies reveal that the molecular weight, monosaccharide compositions, the sulfation degree, and the positions of sulfates influence the renoprotective activity, and that low-molecular-weight fucoidan exhibits better renoprotective activity than higher-molecular-weight fucoidan.
Fucoidan has significant anticoagulant effects — among the most studied of its properties — though these are complex and structure dependent; fucoidan is an effective thrombin and factor Xa inhibitor, with anti-thrombin effects mediated through heparin cofactor II, and other internal and external coagulation factors. Fucoidans have been demonstrated to inhibit or increase coagulation at different concentration ranges; structural features, i.e., molecular weight, molecular weight distribution, degree of sulfation, monosaccharide composition, and different linkages, are known to affect these activities.
A possible explanation of fucoidan's anti-inflammatory effect is the attenuation of the activation of the NF-κB signaling pathway. Other researchers discuss the role of the mitogen-activated protein kinase (MAPK) cascade in the biological effects of fucoidan; the MAPK family consists of serine/threonine protein kinases that are present in many mammalian cells. High-molecular-weight fucoidan extracted from Fucus vesiculosus has also been found to have anti-inflammatory effects that are attributed to its selective inhibition of the cyclooxygenase-2 (COX-2) enzyme.
Fucoidan can induce the production of interleukin-1 (IL-1) and interferon-γ (IFN-γ) in vitro, enhance the functions of T lymphocytes, B cells, macrophages, and natural killer (NK) cells, and promote the primary antibody response in vivo. High-molecular-weight fucoidan prepared from Okinawa mozuku (Cladosiphon okamuranus) promotes an increase in the proportion of murine cytotoxic T cells. Oral fucoidan is responsible for inducing the secretion of the immune-modulatory factor galectin-9 by intestinal epithelial cells.
The main pathways influenced by fucoidan in the anticancer context are the PI3K/AKT pathway, the MAPK pathway, and the caspase pathway. The antitumour mechanisms of fucoidans in tumour cells include cell cycle arrest at the sub-G1 phase, caspase-dependent apoptosis, and regulation of specific apoptotic proteins such as PARP1, PERK, Bcl-2, BAX, and caspases -3, -8, and -9. Independently from their source, fucoidans also inhibit several angiogenic regulators, primarily vascular endothelial growth factor (VEGF).
Studies have suggested that the main target for the antiviral action of fucoidan is virus adsorption. Studied fucoidan compounds were found to inhibit HIV-1 replication at different stages of the virus life cycle; all fucoidans tested exhibited significant antiviral activity by affecting the early stages of the virus–cell interaction.
Anti-hyperglycemic effects of high-molecular-weight fucoidan from Fucus vesiculosus have been attributed to mechanisms including the inhibition of the dipeptidyl peptidase-IV (DPP-IV) enzyme. These versatile marine-origin heteropolysaccharides also possess antioxidant and lipid-lowering activities.
The vast majority of the evidence for fucoidan's anticancer activity comes from in vitro cell studies and in vivo animal models. The antitumour effects of fucoidans have been extensively investigated in vitro in various tumour cell lines, especially in lung and breast cancer cell lines, and in vivo in animal models. A 2021 systematic review and meta-analysis compiled animal experimental data: the objective was to systematically review antitumour activity of fucoidan based on animal experiments, searching databases including the Cochrane Library, PubMed, Ovid MEDLINE, Web of Science, Embase, and others; 23 articles were included, and the results showed that compared with the control group, the fucoidan intervention group had significantly inhibited tumour weight, volume, and number. However, this evidence base is entirely preclinical.
At the clinical level, a 2022 systematic review of human studies found very limited data: four studies were included — one randomised controlled trial and three quasi-experimental studies — with meta-analysis not applied due to heterogeneity; the overall sample size was 118, most participants were metastatic colorectal and gastric cancer patients, and two studies revealed a significantly longer survival time and chemotherapy treatment period with fucoidan use. The authors noted that no published review article had previously investigated the effectiveness of supplemental fucoidan in cancer patients, and there are currently no clinical guidelines for supplementary use of fucoidan in cancer patients.
A phase II randomised, double-blind trial was initiated in 2020 examining fucoidan in combination with standard therapy in head and neck cancer: the study was designed to evaluate the clinical effects and safety of fucoidan combined with chemotherapy and radiation in patients with stage III/IV head and neck squamous cell carcinoma (NCT04597476); 119 patients were randomised 1:1 to receive orally either fucoidan (4.4 g twice daily) or placebo (potato starch 4.4 g twice daily) over a 24-week period, with disease-free survival as the primary outcome.
Research into fucoidan as an immune adjuvant in cancer is also ongoing. Fucoidan compounds may increase immune activity and are known to have cancer inhibitory effects in vitro and in vivo; one study investigated the effect of fucoidan compounds on ex vivo human peripheral blood mononuclear cells (PBMCs) and their cancer cell killing activity both alone and in combination with the immune-checkpoint inhibitor drug Nivolumab, assessing PBMC proliferation and interferon-gamma (IFNγ) release in the presence of fucoidan extracted from Fucus vesiculosus, Undaria pinnatifida, and Macrocystis pyrifera. A clinical trial (NCT06855524) sponsored by Mayo Clinic is currently evaluating how well fucoidan works in preventing chemotherapy-related fatigue compared to placebo in patients with gastrointestinal or gynecological cancer.
Evidence strength (oncology): Predominantly preclinical (cell and animal studies). Human clinical data are very limited, from small and heterogeneous studies. No fucoidan preparation has been approved as an anticancer drug in any jurisdiction. Larger, controlled clinical trials are in progress but have not yet reported completed results.
Studies have shown that fucoidan has curative effects on chronic renal failure, acute kidney injury, and diabetic nephropathy both in vitro and in vivo. Pharmacological studies indicate that fucoidan inhibits renal fibrosis and glomerular sclerosis by reducing the accumulation of extracellular matrix; additionally, fucoidan reduces the inflammatory response and P-selectin expression, maintains the glomerular basement membrane and glomerular structural integrity, improves glomerular filtration function, and protects renal glycosaminoglycans from abnormal degradation.
China is the most advanced jurisdiction in terms of clinical application: clinical use of fucoidan for the treatment of renal disease has become available, and human safety studies have been undertaken. Regulatory approval of a fucoidan preparation for chronic renal failure has provided clinically useful outcomes in China. Modern pharmacological investigation of marine brown algae (Saccharina japonica), traditionally used in medicine for conditions such as "edema," reveals that their principal active component, fucoidan, is a sulfated polysaccharide with marked physicochemical similarities to endogenous heparan sulfate.
In preclinical work, fucoidan (at 100 and 200 mg/kg) significantly reversed adenine-induced high expression of urea, uric acid, and creatinine in serum, as well as novel object recognition memory and spatial memory deficits in a CKD mouse model; RNA sequencing indicated that fucoidan inhibited oxidative stress via GSK3β-Nrf2-HO-1 signaling and ameliorated inflammatory response through regulation of microglia/macrophage polarization in the kidney and hippocampus.
Existing clinical studies — mostly of weeks to months duration — report adverse events primarily as mild, reversible gastrointestinal discomfort, with incidence rates not significantly different from conventional treatment groups, indicating good short-term tolerability; however, long-term safety of fucoidan (especially oral LMW products) requires confirmation via longer follow-up studies.
Evidence strength (renal): There is regulatory-backed clinical use in China. The broader mechanistic and pharmacological evidence is robust in preclinical models. Independent large RCTs in Western populations are lacking.
Fucoidan has been shown to alleviate atherosclerotic lesions through its anti-inflammatory and anticoagulant effects. Moreover, fucoidan has been shown to suppress neointima formation and reduce adverse vascular remodeling. In terms of the anticoagulant mechanism, fucoidan, a sulfated polysaccharide from brown algae, could prevent coagulation and thrombus after intravenous administration.
A pilot human clinical trial examining oral anticoagulant effects was published: this pilot clinical trial assessed the safety and clinical effects of fucoidan ingestion on haemostasis; in a single-blinded design, 20 human volunteers were allocated to a placebo group (n=10) who ingested 3 g of guar gum capsules and to an active treatment group (n=10) who ingested 3 g of 75% fucoidan capsules for 12 days. Despite all the success in animal models, IV administration of fucoidan as a therapeutic drug has not been studied in human clinical trials.
Oral pharmacokinetics studies show that pharmacokinetic and tissue distribution studies of orally administered fucoidan from Fucus vesiculosus showed that fucoidan preferentially accumulated in kidney, spleen, and liver, with an extended mean residence time in blood.
Evidence strength (cardiovascular): Preclinical evidence is well-established. Human pharmacokinetic data exist in limited form. Controlled clinical trials on cardiovascular endpoints are absent.
In the early 1980s, fucoidans were first recognised for their role in supporting the immune response, and later, in the 1990s, their effects on immune potentiation began to emerge; in recent years the understanding of the immunomodulatory effects of fucoidan has expanded significantly. The ability of fucoidan to activate cytotoxic T lymphocyte (CTL)-mediated cytotoxicity against cancer cells, combined with its strong antitumour properties and robust safety profile, makes fucoidans desirable for effective cancer immunotherapy.
Intranasal administration of fucoidan extracted from Ecklonia cava showed a promising synergistic effect on metastatic lung cancer cells in mice with anti-PD-L1; fucoidan activated a variety of immune cells including dendritic cells, natural killer (NK) cells, and T cells in the mediastinal lymph node.
Evidence strength (immune): Extensive in vitro and animal data. Human immune cell studies (ex vivo) are promising. Controlled clinical trials in humans are at an early stage.
Both native and enzyme-modified fucoidans from Fucus evanescens significantly inhibited virus-induced cytopathic effects in vitro, and were most effective against herpes simplex virus (HSV). Cytotoxicity data showed low toxicity of native and modified fucoidans against Vero cells, with 50% cytotoxic concentrations above 2000 µg/mL, compared to 750 µg/mL for ribavirin. Due to developing resistance to antiretroviral drugs, there is demand for alternative agents; research has examined fucoidans from multiple brown algae species for anti-HIV-1 activity in vitro, and all studied compounds were found to inhibit HIV-1 replication at different stages of the viral life cycle, with all exhibiting significant antiviral activity by affecting early stages of the virus–cell interaction.
Evidence strength (antiviral): Almost entirely in vitro and in vivo animal data. No human clinical trials on antiviral outcomes have been completed. The evidence is preliminary and promising but not sufficient to support therapeutic claims in humans.
A 2023 open-label randomised controlled trial examined fucoidan in the context of H. pylori eradication: the study assessed the clinical efficacy of fucoidan-assisted standard quadruple therapy (SQT) for H. pylori eradication and improvement of gut microbiota; conducted at the Affiliated Hospital of Qingdao University, China, 90 H. pylori-positive patients were randomised to an SQT group, an SQT + fucoidan combination group, and a fucoidan-before-SQT group, with stool samples collected for gut microbiota composition. Fucoidan considerably improved gut dysbiosis during SQT, and gut microbiota could be maintained by adding fucoidan before eradication therapy rather than concomitantly.
Regarding gut microbiota modulation more broadly, microbiome modulation and anti-pathogenic effects are increasingly promising applications for fucoidans, due to the need for alternative approaches to antibiotic use in the food chain.
Evidence strength (gastrointestinal): One small RCT supports a role for fucoidan in attenuating antibiotic-induced gut dysbiosis during H. pylori therapy. Prebiotic and microbiome-modulating properties are supported by animal and preliminary human data. Further controlled trials are needed.
The anti-inflammatory action of fucoidans is well established based on both in vitro and some in vivo studies. Beneficial effects on inflammatory diseases — including pancreatitis, colitis, osteoarthritis, and skin inflammation — as well as neurodegenerative diseases, immune dysfunction, and tumours have been an object of intensive research. In vitro, a low-molecular-weight fucoidan inhibited human rheumatoid arthritis fibroblast synoviocytes and triggered apoptosis via decreased expression and secretion of matrix metalloproteinases MMP-1, MMP-3, and MMP-9, and suppression of NF-κB binding activity.
Evidence strength (inflammation): Robust in vitro and animal data. Mechanistic pathways are well characterised. Human clinical trial data for specific inflammatory diseases are lacking.
Various pharmacological effects including antidiabetic and nephroprotective properties have been reported. Low-molecular-weight fucoidan was shown to protect kidneys from dysfunction and fibrogenesis by inhibiting the TGF-β pathway in a diabetic nephropathy rat model. Anti-hyperglycaemic effects of high-molecular-weight fucoidan from Fucus vesiculosus have been attributed to the inhibition of the dipeptidyl peptidase-IV (DPP-IV) enzyme.
Evidence strength (metabolic/antidiabetic): Predominantly preclinical. No controlled human trials specifically addressing glycaemic endpoints with fucoidan have been published as of the available evidence base.
Fucoidans have been shown to exhibit a variety of beneficial pharmacological effects, including antitumour, anti-inflammatory, immunomodulatory, antioxidant, anticoagulant, antithrombotic, antiangiogenic, and antiviral properties. Pharmacological effects additionally reported include antimicrobial, antidiabetic, and nephroprotective activities. The major body systems and health areas to which fucoidan research has been directed are summarised below:
There is no universally established therapeutic dose for fucoidan in humans. Dosages reported in published studies vary considerably by indication, molecular weight fraction, and species of origin:
Low-molecular-weight fucoidan (LMWF) has been found to have much better absorption and bioavailability than medium-molecular-weight fucoidan. Tissue distribution studies of orally administered fucoidan from Fucus vesiculosus showed that it preferentially accumulated in kidney, spleen, and liver, with an extended mean residence time in blood.
Fucoidan is generally considered non-toxic and rarely causes irritation reactions. Existing clinical studies, mostly of weeks to months duration, report adverse events primarily as mild, reversible gastrointestinal discomfort, with incidence rates not significantly different from conventional treatment groups, indicating good short-term tolerability. However, the long-term safety of fucoidan — especially oral LMW products — requires confirmation via longer follow-up studies.
The most pharmacologically significant and well-documented safety concern for fucoidan is its intrinsic anticoagulant activity. Because fucoidan demonstrates anticoagulant and antithrombotic activities, it may have additive effects when taken with anticoagulants. Specifically, anticoagulants such as warfarin and heparin may interact with fucoidan, with the potential to increase bleeding risk due to its antithrombotic effects. Particular attention should be paid to fucoidan's heparin-like anticoagulant and antiplatelet activity; in advanced CKD patients — who often have coagulation abnormalities and may be on antithrombotic agents — long-term supplementation could interfere with coagulation balance and increase bleeding risk.
Fucoidan also has affinity for P-selectin that is expressed by activated platelets in the thrombus, enhancing the risk of bleeding if injected with recombinant tissue plasminogen activator due to thrombolysis. Preclinical studies suggest that intravenous administration may significantly prolong clotting time, posing a potential bleeding risk.
In a small study of breast cancer patients, co-administration of fucoidan with either of two hormonal therapies — letrozole or tamoxifen — was well tolerated and did not result in any clinically significant interactions. It is important to screen for interactions between therapeutics and compounds such as fucoidan that may be present in complementary medicines.
Although used in traditional Chinese medicine, fucoidan has not been approved as a human drug in any country outside China, and no advanced clinical trials had been reported as of 2019. It is commonly used in Southeast Asian countries and is recognised as a natural health product in Canada, but does not have governmental approval or recognition as a safe ingredient for human use in most Western countries.
Health conditions that Fucoidan may help support.
Fucoidan, a sulfated polysaccharide from brown algae, modulates immune responses with established immunomodulatory effects relevant to autoimmune conditions. It promotes NK cell activity, modulates T-cell and cytokine responses, and has shown anti-inflammatory effects in RA and IBD animal models and human studies.
Fucoidan is a sulfated polysaccharide from brown algae with heparin-like anticoagulant activity, inhibiting thrombin, reducing platelet aggregation, and prolonging APTT and PT. An authoritative PubMed review specifically identifies fucus (fucoidan source) as having heparin-like antithrombotic activity. Multiple in vitro and animal studies support its antithrombotic effects.
Fucoidan, a sulfated polysaccharide from brown seaweed, has demonstrated anti-inflammatory effects in both preclinical models and human clinical studies. Its primary mechanisms involve downregulation of the NF-κB and MAPK signaling pathways, reducing pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Human trials—particularly in cancer patients and asthmatic patients—have recorded statistically significant reductions in chronic inflammatory biomarkers. Evidence is promising but largely limited to small or open-label trials; large randomized controlled trials are still lacking.
Fucoidan is a sulfated polysaccharide from brown seaweed with documented prebiotic activity and gut microbiota modulation capacity. Multiple in vitro and preclinical studies show it increases Bifidobacterium and Lactobacillus while inhibiting pathogens; emerging human studies confirm gut microbiome-modulating effects.
Fucoidan is a sulfated polysaccharide from brown algae with immunomodulatory, antioxidant, and anti-inflammatory properties. Multiple human clinical trials demonstrate fucoidan reduces oxidative stress markers, modulates immune aging, and supports gut health. Preclinical evidence suggests telomerase-activating and anti-senescence effects relevant to healthy aging.
Fucoidan is a sulfated polysaccharide from brown seaweeds with documented antiviral activity against multiple viruses including HSV, norovirus, influenza, HIV, and dengue. It inhibits viral attachment to host cells by competing with heparan sulfate binding sites. Multiple in vitro and some clinical studies support its antiviral immune properties.
Body systems that Fucoidan may help support.
Go back